FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2909969046> ?p ?o ?g. }

• W2909969046 endingPage "335" @default.
• W2909969046 startingPage "328" @default.
• W2909969046 abstract "To estimate the drug administration, travelling, and productivity costs associated with infusion or subcutaneous proteasome inhibitor (PI) treatments (specifically carfilzomib and bortezomib) for multiple myeloma (MM) patients in Finland.Price tariffs of Finnish hospital districts are used as the basis of invoicing sent to healthcare service payers. A review of these price tariff lists was conducted and obtained data analysed to estimate the mean unit cost of PI administration visit. Travelling costs stratified by areas with different population densities were assessed, based on the national travelling reimbursement register data maintained by the Social Insurance Institution of Finland. Productivity costs due to time spent on administration visits and travelling were estimated based on an expert interview and a spatial healthcare accessibility analysis.Nineteen (95%) of the Finnish hospital districts were included in the review. Relevant unit cost information was found for 15 (75%) of the districts. The mean PI administration cost alone was 270€ (95% CI = 189€-351€) per administration and increased to 371€ when travelling costs were included. Productivity costs added, the mean PI administration costs totalled 405€ for bortezomib and 437€ for carfilzomib.The costing rationale of price tariffs may vary between hospital districts. Productivity costs were estimated conservatively, due to lack of data.The administration of intravenous or subcutaneous PIs to treat MM in healthcare facilities causes significant and potentially avoidable healthcare, travelling, and indirect costs, and they should be included in all health economic evaluations (HEEs). As the cost estimates utilized in this study represent most of central hospitals in the country, they provide useful information for future HEEs. A broader conclusion is that novel oral medications, such as the first oral PI, have a significant potential for reducing administration-related costs of subcutaneous or intravenous PIs." @default.
• W2909969046 created "2019-01-25" @default.
• W2909969046 creator A5031882178 @default.
• W2909969046 creator A5063115075 @default.
• W2909969046 creator A5063275766 @default.
• W2909969046 creator A5070019599 @default.
• W2909969046 creator A5078379954 @default.
• W2909969046 date "2019-02-04" @default.
• W2909969046 modified "2023-09-26" @default.
• W2909969046 title "Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland" @default.
• W2909969046 cites W1535093614 @default.
• W2909969046 cites W1536921365 @default.
• W2909969046 cites W1985864219 @default.
• W2909969046 cites W1990152834 @default.
• W2909969046 cites W2003920534 @default.
• W2909969046 cites W2042592602 @default.
• W2909969046 cites W2075016698 @default.
• W2909969046 cites W2083713174 @default.
• W2909969046 cites W2146073152 @default.
• W2909969046 cites W2201190784 @default.
• W2909969046 cites W2272567705 @default.
• W2909969046 cites W2475799443 @default.
• W2909969046 cites W2509578420 @default.
• W2909969046 cites W2514361541 @default.
• W2909969046 cites W2524550612 @default.
• W2909969046 cites W2528329272 @default.
• W2909969046 cites W2587819645 @default.
• W2909969046 cites W2589691843 @default.
• W2909969046 cites W2765701318 @default.
• W2909969046 cites W2805512163 @default.
• W2909969046 cites W2903371179 @default.
• W2909969046 cites W394822595 @default.
• W2909969046 cites W4211037848 @default.
• W2909969046 doi "https://doi.org/10.1080/13696998.2019.1569457" @default.
• W2909969046 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30644325" @default.
• W2909969046 hasPublicationYear "2019" @default.
• W2909969046 type Work @default.
• W2909969046 sameAs 2909969046 @default.
• W2909969046 citedByCount "9" @default.
• W2909969046 countsByYear W29099690462019 @default.
• W2909969046 countsByYear W29099690462020 @default.
• W2909969046 countsByYear W29099690462021 @default.
• W2909969046 countsByYear W29099690462022 @default.
• W2909969046 countsByYear W29099690462023 @default.
• W2909969046 crossrefType "journal-article" @default.
• W2909969046 hasAuthorship W2909969046A5031882178 @default.
• W2909969046 hasAuthorship W2909969046A5063115075 @default.
• W2909969046 hasAuthorship W2909969046A5063275766 @default.
• W2909969046 hasAuthorship W2909969046A5070019599 @default.
• W2909969046 hasAuthorship W2909969046A5078379954 @default.
• W2909969046 hasConcept C121955636 @default.
• W2909969046 hasConcept C126322002 @default.
• W2909969046 hasConcept C137992405 @default.
• W2909969046 hasConcept C138816342 @default.
• W2909969046 hasConcept C144133560 @default.
• W2909969046 hasConcept C159110408 @default.
• W2909969046 hasConcept C160735492 @default.
• W2909969046 hasConcept C162324750 @default.
• W2909969046 hasConcept C164624739 @default.
• W2909969046 hasConcept C175444787 @default.
• W2909969046 hasConcept C17744445 @default.
• W2909969046 hasConcept C194828623 @default.
• W2909969046 hasConcept C199539241 @default.
• W2909969046 hasConcept C204983608 @default.
• W2909969046 hasConcept C2776364478 @default.
• W2909969046 hasConcept C2777478702 @default.
• W2909969046 hasConcept C2779703844 @default.
• W2909969046 hasConcept C2780108899 @default.
• W2909969046 hasConcept C2780765947 @default.
• W2909969046 hasConcept C50522688 @default.
• W2909969046 hasConcept C524218345 @default.
• W2909969046 hasConcept C71924100 @default.
• W2909969046 hasConcept C87864170 @default.
• W2909969046 hasConceptScore W2909969046C121955636 @default.
• W2909969046 hasConceptScore W2909969046C126322002 @default.
• W2909969046 hasConceptScore W2909969046C137992405 @default.
• W2909969046 hasConceptScore W2909969046C138816342 @default.
• W2909969046 hasConceptScore W2909969046C144133560 @default.
• W2909969046 hasConceptScore W2909969046C159110408 @default.
• W2909969046 hasConceptScore W2909969046C160735492 @default.
• W2909969046 hasConceptScore W2909969046C162324750 @default.
• W2909969046 hasConceptScore W2909969046C164624739 @default.
• W2909969046 hasConceptScore W2909969046C175444787 @default.
• W2909969046 hasConceptScore W2909969046C17744445 @default.
• W2909969046 hasConceptScore W2909969046C194828623 @default.
• W2909969046 hasConceptScore W2909969046C199539241 @default.
• W2909969046 hasConceptScore W2909969046C204983608 @default.
• W2909969046 hasConceptScore W2909969046C2776364478 @default.
• W2909969046 hasConceptScore W2909969046C2777478702 @default.
• W2909969046 hasConceptScore W2909969046C2779703844 @default.
• W2909969046 hasConceptScore W2909969046C2780108899 @default.
• W2909969046 hasConceptScore W2909969046C2780765947 @default.
• W2909969046 hasConceptScore W2909969046C50522688 @default.
• W2909969046 hasConceptScore W2909969046C524218345 @default.
• W2909969046 hasConceptScore W2909969046C71924100 @default.
• W2909969046 hasConceptScore W2909969046C87864170 @default.
• W2909969046 hasIssue "4" @default.
• W2909969046 hasLocation W29099690461 @default.

• next